At the SGC, Susanne has mainly worked with the biotechnology groups at several sites, developing methods for high-throughput production of human proteins for crystallization and to be used as antigens for the generation of recombinant antibodies. She now heads the Recombinant antibodies group at SGC Karolinska, which generates recombinant antibodies to selected SGC target proteins. Her group is currently funded by the IMI project ULTRA-DD, and focus is to generate antibodies to target proteins involved in inflammatory processes and autoimmune disease.
The Recombinant antibodies group has set up a similar pipeline for protein production as is being used by the Biotechnology groups at SGC Oxford and Toronto. We have established protocols for high-throughput cloning, test expression/purification, large-scale expression in E.coli and parallel protein production and validation.
We collaborate closely with the Human Recombinant Antibodies team at the Drug Discovery and Development platform at the Science for Life Laboratory in Stockholm. We share both lab space and staff and thus have access to state-of –the-art combinatorial libraries of antibody fragments and a fully equipped phage display laboratory where recombinant antibodies are selected.
Antibody candidates are validated first through kinetic studies of binding to the antigen through SPR. Binders with good enough affinities are then tested in cell-based assays towards the full-length endogenous target protein from a suitable cell type using IP-MS.
Current throughput is cloning and large-scale production of approximately 100 proteins per year and phage display selections on about 50 antigens. The current success rate for obtaining an IP-MS-competent antibody is about 66% if we could make an antigen batch.